North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 9 of 9
Details
UPD
sitematrix Changed from 0 to
10/10/2023 16:21:17
(LoweryM )
UPD
FurtherInformation Changed from
130 mg concentrate for solution for infusion
Approved for previously treated moderately to severely active Crohn’s disease in adults in line with NICE
Approved for treating
10/10/2023 16:21:17
(LoweryM )
UPD
Ustekinumab (Stelara
®
) approved
10/10/2023 16:21:17
(LoweryM )
LDL
Link Added : MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis : https://www.gov.uk/drug-safety-update/ustekinumab-stelara-risk-of-exfoliative-dermatitis
11/07/2023 16:07:27
(ebeavers )
LDL
Link Added : NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis : https://www.nice.org.uk/guidance/ta633
30/10/2020 16:30:28
(DavidS )
UPD
Ustekinumab (Stelara
®
) updated
30/10/2020 16:29:56
(DavidS )
UPD
Published from Draft Mode
27/10/2017 15:19:34
(DavidS )
LDL
Link Added : NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment : https://www.nice.org.uk/guidance/ta456
26/10/2017 16:35:52
(DavidS )
ADD
Ustekinumab (Stelara
®
) NICE TA456
26/10/2017 16:35:15
(DavidS )